Abstract
Acambis, in collaboration with Aventis Pasteur, is developing a chimeric vaccine based on a recombinant yellow fever vaccine for the potential prevention of dengue virus infection. The vaccine is undergoing phase I clinical trials.
MeSH terms
-
Animals
-
Antibodies, Viral / blood
-
Child
-
Clinical Trials, Phase I as Topic
-
Dengue / prevention & control*
-
Dengue Virus / genetics*
-
Dengue Virus / immunology*
-
Dengue Virus / pathogenicity
-
Drug Evaluation, Preclinical
-
Humans
-
Severe Dengue / prevention & control*
-
Vaccines, Synthetic / adverse effects
-
Vaccines, Synthetic / immunology
-
Vaccines, Synthetic / toxicity
-
Viral Vaccines* / adverse effects
-
Viral Vaccines* / therapeutic use
-
Viral Vaccines* / toxicity
-
West Nile Virus Vaccines
Substances
-
Antibodies, Viral
-
ChimeriVax
-
Vaccines, Synthetic
-
Viral Vaccines
-
West Nile Virus Vaccines